Boston Scientific Corp. stock (US10117L1017): shares steady on Nasdaq as investors digest recent Q1 update

Boston Scientific Corp. is trading little changed on Nasdaq on 06/02/2026 as the market continues to digest the company’s April 2026 first-quarter results and guidance, keeping attention on the United States-based medtech group’s growth momentum in cardiovascular and neuromodulation devices.

Boston Scientific Corp. shares were broadly stable on Nasdaq on 06/02/2026 as investors continued to weigh the United States medtech company’s first-quarter 2026 figures and outlook released in late April, which confirmed solid top-line growth and reiterated confidence in full-year guidance, keeping the stock in focus within the S&P 500 health-care cohort, according to Reuters as of 04/24/2026.

The stock traded around the low-80s USD range on Nasdaq on 06/02/2026, with only a modest percentage move compared with the previous close, while trading volumes remained broadly in line with recent averages, according to Nasdaq data as of 06/02/2026. The shares continue to reflect expectations for double-digit operational growth in key franchises following the latest quarterly numbers, which were reported in US dollars and filed with the US Securities and Exchange Commission.

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Boston Scientific
• Sector/industry: Medical technology and cardiovascular devices
• Headquarters/country: Marlborough, United States
• Core markets: North America, Europe, Asia-Pacific and Latin America
• Key revenue drivers: Interventional cardiology, cardiac rhythm management, endoscopy and neuromodulation product lines
• Home exchange/listing venue: Nasdaq (BSX)
• Trading currency: USD

Boston Scientific Corp.: core business model

Boston Scientific focuses on designing, manufacturing and selling minimally invasive medical devices used in interventional cardiology, structural heart, electrophysiology, endoscopy, urology and neuromodulation procedures, with revenue primarily driven by recurring demand from hospitals and health-care providers for its implantable devices and disposable interventional products.

Latest quarterly results for Boston Scientific Corp. at a glance

For the quarter ended 03/31/2026, which Boston Scientific reported on 04/24/2026, the company posted higher sales compared with the prior year, supported by growth in cardiovascular and med-surg segments, according to a company press release published on its investor-relations site on 04/24/2026. Management highlighted continued momentum in structural heart therapies and electrophysiology, segments that have been key contributors to overall revenue expansion in recent periods, according to the same Boston Scientific release dated 04/24/2026.

The company also reiterated confidence in its full-year 2026 outlook when presenting the first-quarter figures on 04/24/2026, according to the investor presentation filed with the SEC on that date. The guidance framework continues to assume ongoing procedure recovery in major markets such as the United States and Europe as well as contributions from recently launched devices across interventional cardiology, neuromodulation and urology.

Conclusion

With Boston Scientific Corp.’s shares moving sideways on Nasdaq on 06/02/2026, the market’s attention remains centered on the company’s April 2026 first-quarter update and reaffirmed confidence in its 2026 outlook. The latest results underline the importance of cardiovascular and med-surg franchises to the group’s growth profile, and investors will be watching subsequent quarters to see whether procedure trends and product launches sustain the current momentum embedded in expectations for the United States medical-technology leader.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.